Dupilumab (Dupixent) has gained FDA approval for the treatment of chronic rhinosinusitis with nasal polyps, marking the first biologic approved for adults with inadequately controlled disease. Chronic ...

Researchers conducted an indirect treatment comparison (Bucher method) using placebo as a common comparator to evaluate the efficacy of dupilumab and tezepelumab in patients with CRSwNP. The analysis ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content. Nasal polyp development, treatment, and recurrence, as well ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prevalence of type 2 inflammation ranged from 64.2% to ...

Please provide your email address to receive an email when new articles are posted on . Three currently available type 2 biologics approved for asthma appeared effective in treating chronic ...

GSK has secured European Commission approval for Exdensur (depemokimab) to treat severe asthma with type 2 inflammation and ...

Competition among biologics that target inflammatory respiratory disease is heating up even further. On Thursday, AstraZeneca said its Fasenra, used in tandem with standard steroids, significantly ...

Nasal polyps are common, affecting up to 4% of the general population, and can affect quality of life, but are usually benign. However, a new study suggests that when they occur in older patients (≥ ...